Wall Street analyst estimates for Rhythm Pharmaceuticals, Inc. (RYTM): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
Consensus price target
$144.43 (+67 % vs price $86.44)
between $120.00 and $160.00 · 5 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $318M | $311M – $329M | -$2.95 | 12 |
| 2027E | $562M | $510M – $633M | -$0.65 | 12 |
| 2028E | $896M | $668M – $1.2B | $2.61 | 11 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 22 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 22 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.71 | ||
| 2026-08-04 | $-0.73 | $-0.81 | +9.6% |
| 2026-05-05 | $-0.83 | $-0.86 | +3.5% |
| 2026-02-26 | $-0.73 | $-0.79 | +7.6% |
| 2025-11-04 | $-0.82 | $-0.72 | -13.9% |
| 2025-08-05 | $-0.75 | $-0.66 | -13.6% |
| 2025-05-07 | $-0.81 | $-0.69 | -17.4% |
| 2025-02-26 | $-0.72 | $-0.69 | -4.3% |
Valuation Ratios
| Price / Book | 29.61 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| Cost of Revenue | $144,000 | $223,000 | $442,000 | $834,000 | $690,000 | $599,000 | $2.1M | $9.3M | $13.4M | $19.5M |
| Gross Profit | -$144,000 | -$223,000 | -$442,000 | -$834,000 | -$690,000 | $2.6M | $21.5M | $68.1M | $116.8M | $170.3M |
| Research & Development | $19.6M | $22.9M | $50.3M | $109.5M | $90.5M | $104.1M | $108.6M | $135.0M | $238.0M | $167.3M |
| Selling, General & Admin | $6.3M | $9.5M | $28.1M | $36.5M | $46.1M | $68.5M | $92.0M | $117.5M | $144.3M | $194.9M |
| Operating Expenses | $25.9M | $32.4M | $78.4M | $145.2M | $135.9M | $172.6M | $200.7M | $252.5M | $382.3M | $362.3M |
| Operating Income | -$25.9M | -$32.4M | -$78.4M | -$146.0M | -$136.6M | -$170.1M | -$179.2M | -$184.4M | -$265.5M | -$192.0M |
| EBITDA | -$25.8M | -$32.2M | -$78.0M | -$145.2M | -$135.9M | -$68.5M | -$174.2M | -$168.5M | -$238.1M | -$174.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | $5.2M | $13.9M | $20.6M | $20.6M |
| Pre-tax Income | -$25.9M | -$33.7M | -$74.1M | -$140.7M | -$134.0M | -$69.6M | -$181.1M | -$184.1M | -$260.3M | -$196.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $564,000 | $346,000 | $497,000 |
| Net Income | -$25.9M | -$33.7M | -$74.1M | -$134.6M | -$130.7M | -$69.6M | -$181.1M | -$184.7M | -$260.6M | -$196.5M |
| EPS | -$1.55 | -$1.26 | -$2.39 | -$3.70 | -$2.96 | -$1.37 | -$3.51 | -$3.20 | -$4.34 | -$3.11 |
| EPS (Diluted) | -$1.55 | -$1.26 | -$2.39 | -$3.70 | -$2.96 | -$1.37 | -$3.51 | -$3.20 | -$4.34 | -$3.11 |
| Shares Outstanding (Diluted) | 16.7 M | 26.7 M | 31.0 M | 36.4 M | 44.1 M | 49.6 M | 52.1 M | 57.7 M | 61.0 M | 65.0 M |
Price
| Price | $86.44 (closing price, November 3, 2026) |
| Market Cap | $6.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BMRN · BLTE · VKTX · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of RYTM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks